サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：プラバスタチン市場2022-2028
市場調査レポート
商品コード
1215663

プラバスタチン市場2022-2028

Pravastatin Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
プラバスタチン市場2022-2028
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

プラバスタチンの世界市場は、予測期間中にCAGR5.4％で成長すると予測されています。製薬研究活動の高まりは、市場に開発機会を生み出しています。例えば、2021年7月には、2020年1月から9月にかけて米国の病院全体で、スタチンが高血圧や心臓病の既往を持つCOVID-19患者の死亡リスクを低減することを示す研究が実施されました。この研究は、米国の104の病院において、約10,500人の患者さんを対象に行われました。全員がCOVID-19の重篤な疾患で入院していました。米国心臓協会によるデータ解析の結果、スタチンの使用は、同様にCOVID-19感染による重篤な転帰の発生リスクを25％低下させるという結論に至っています。プラバスタチンは、血中のLDL（悪玉）コレステロールとトリグリセリドを減らし、HDL（善玉）コレステロールを増加させる。ジェネリック医薬品としてのみ販売されており、先発医薬品はありません。また、錠剤の形態でのみ販売されています。本レポートではさらに、予測期間中にプラバスタチン市場の成長に直接的または間接的に影響を与える一次要因だけでなく二次要因もすべて分析する予定です。

プラバスタチンの世界市場は、投与量タイプおよびエンドユーザーに基づいて区分されます。投与量タイプに基づき、市場は10 mg錠、20 mg錠、40 mg錠、80 mg錠に区分されます。エンドユーザーに基づけば、市場は小児と成人に細分化されます。これらのセグメントはさらに、要求された調査要件に従ってカスタマイズすることができます。

地域的には、世界のプラバスタチン市場は、北米、欧州、アジア太平洋地域、その他の地域に区分されます。また、ご要望に応じて、特定の地域や国レベルでの市場分析も可能です。プラバスタチンの世界市場では、欧州がかなりのシェアを占めています。欧州市場の成長を促進する要因としては、心血管障害の有病率の上昇などが挙げられます。欧州心血管疾患統計2017によると、欧州では毎年390万人の心血管疾患による死亡が報告されており、EUパートナー国では毎年180万人の死亡が報告されています。これは、欧州全体、EU全体で登録された死亡者数のそれぞれ45％、37％に相当します。したがって、心血管疾患の負担の増加は、この地域におけるプラバスタチン医薬品の需要を増加させるでしょう。

目次

第1章 レポート概要

  • 現在の産業分析と成長性の展望
  • COVID-19がプラバスタチンの世界市場に与える影響
  • プラバスタチンの世界市場の回復シナリオ
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場の概要とインサイト

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • レコメンデーション
    • まとめ

第3章 競合情勢

  • 主要企業分析
    • Bristol-Myers Squibb, Co.
    • Novartis International AG
    • Glenmark Pharmaceuticals Ltd.
    • Dr. Reddy's Laboratories, Ltd.
  • 主要戦略分析
  • COVID-19が主要プレイヤーに与える影響

第4章 市場セグメンテーション

  • プラバスタチンの世界市場：投与量タイプ別
    • 10mg錠剤
    • 20mg錠剤
    • 40mg錠
    • 80mg錠
  • プラバスタチンの世界市場：エンドユーザー別
    • 小児
    • 成人

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Accord Healthcare, Ltd.
  • Apotex, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla, Inc.
  • Daiichi Sankyo Co
  • Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • Lupin Ltd.
  • Mylan N.V.
  • North China Pharmaceutical Group
  • Shanghai Shyndec Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zydus Pharmaceuticals, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 7. GLOBAL PRAVASTATIN FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL PRAVASTATIN FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 13. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 14. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 15. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL PRAVASTATIN MARKET, 2021-2028 ($ MILLION)
  • 2. GLOBAL PRAVASTATIN MARKET SHARE BY DOSAGE TYPE, 2021 VS 2028 (%)
  • 3. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL PRAVASTATIN MARKET SHARE BY END USER, 2021 VS 2028 (%)
  • 8. GLOBAL PRAVASTATIN FOR CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL PRAVASTATIN OF ADULTS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL PRAVASTATIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. US PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. CANADA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. UK PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. FRANCE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. GERMANY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. ITALY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. SPAIN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. REST OF EUROPE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. INDIA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. CHINA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. JAPAN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF ASIA-PACIFIC PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026719

Title:Global Pravastatin Market Size, Share, and Trends Analysis Report, by Dosage Type (10 mg Tablet, 20 mg Tablet, 40 mg Tablet, and 80 mg Tablet) and by End User (Children and Adults), Forecast Period (2022-2028).

The global pravastatin market is anticipated to grow at a CAGR of 5.4% during the forecast period. The rising pharmaceutical research activities are generating development opportunities for the market. For instance, in July 2021, a study was conducted across the US hospitals between January and September 2020 to show that the Statins reduce the risk of mortality in COVID-19 patients with a history of high blood pressure or heart disease. The study was conducted on around 10,500 patients across 104 US hospitals. All of them had been admitted with a serious COVID-19 disease. After analyzing the data by American Heart Association, it was concluded that statin use was similarly linked to a 25% lower risk for developing a severe outcome as a result of COVID-19 infection. Pravastatin reduces LDL (bad) cholesterol and triglycerides in the blood and increases HDL (good) cholesterol. It is only available as a generic drug and it doesn't have a brand name version. It comes only in the form of a tablet. This report will further analyze all the primary as well as secondary factors that are directly or indirectly influencing the growth of the pravastatin market during the forecast period.

The global pravastatin market is segmented based on dosage type and end-users. Based on the dosage type, the market is segmented into 10 mg tablets, 20 mg tablets, 40 mg tablets, and 80 mg tablets. Based on the end-users, the market is sub-segmented into children and adults. These segments can further be customized as per the requested research requirements.

Geographically, the global pravastatin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market can also be analyzed for a particular region or country level as per the requirement. Europe holds a considerable share in the global pravastatin market. The factors driving the European market growth include the rising prevalence of cardiovascular disorders. According to the European Cardiovascular Disease Statistics 2017, there were 3.9 million fatalities reported due to cardiovascular diseases every year in Europe, while 1.8 million deaths were reported in the EU partner nations every year. This represents 45% and 37% of the total fatalities registered across the Europe and EU respectively. Thus, the rising burden of cardiovascular disease will increase the demand for pravastatin drugs in this region.

The major companies serving the global pravastatin market include Bristol-Myers Squibb, Novartis International AG, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Inc., Lupin Ltd., Aurobindo Pharma Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global pravastatin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Pravastatin Market Research and Analysis by Dosage Type.
  • Global Pravastatin Market Research and Analysis by End User.

The Report Covers:

  • Comprehensive research methodology of the global pravastatin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pravastatin market.
  • Insights about market determinants that are stimulating the global pravastatin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Pravastatin Market
  • Recovery Scenario of Global Pravastatin Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Bristol-Myers Squibb, Co.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Novartis International AG
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Glenmark Pharmaceuticals Ltd.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Dr. Reddy's Laboratories, Ltd.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Pravastatin Market by Dosage Type
    • 4.1.1. 10 mg Tablet
    • 4.1.2. 20 mg Tablet
    • 4.1.3. 40 mg Tablet
    • 4.1.4. 80 mg Tablet
  • 4.2. Global Pravastatin Market by End User
    • 4.2.1. Children
    • 4.2.2. Adults

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Accord Healthcare, Ltd.
  • 6.2. Apotex, Inc.
  • 6.3. Aurobindo Pharma Ltd.
  • 6.4. Cipla, Inc.
  • 6.5. Daiichi Sankyo Co
  • 6.6. Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • 6.7. Lupin Ltd.
  • 6.8. Mylan N.V.
  • 6.9. North China Pharmaceutical Group
  • 6.10. Shanghai Shyndec Pharmaceutical Co. Ltd.
  • 6.11. Teva Pharmaceutical Industries Ltd.
  • 6.12. Upsher-Smith Laboratories, LLC
  • 6.13. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 6.14. Zydus Pharmaceuticals, Inc.